Solid dose delivery vehicle and methods of making same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/50
출원번호
UP-0134700
(2005-05-20)
등록번호
US-7785631
(2010-09-20)
발명자
/ 주소
Roser, Bruce J.
Kampinga, Jaap
Colaco, Camilo
Blair, Julian
출원인 / 주소
Quadrant Drug Delivery Limited
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
16인용 특허 :
324
초록▼
The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass lo
The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.
대표청구항▼
What is claimed is: 1. A therapeutic composition in solid dose form comprising a bioactive material and a carbohydrate, wherein a) the bioactive material is a protein, b) the therapeutic composition is a powder comprising therapeutic particles having a particle size distribution suitable for pulmon
What is claimed is: 1. A therapeutic composition in solid dose form comprising a bioactive material and a carbohydrate, wherein a) the bioactive material is a protein, b) the therapeutic composition is a powder comprising therapeutic particles having a particle size distribution suitable for pulmonary administration, c) the therapeutic particles are in a glassy state, d) the bioactive material and the carbohydrate are dispersed within the therapeutic particles of the powder, e) the carbohydrate is selected from the group consisting of monosaccharides, disaccharides and sugar alcohols, f) the therapeutic particles remain in the glassy state when stored at elevated temperature, wherein the elevated temperature is 60° C., g) the protein is distributed homogeneously and in solid solution in the carbohydrate, and h) the therapeutic particles have a mean particle size of 0.5 to 5 μm. 2. The therapeutic composition according to claim 1, the therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction. 3. The therapeutic composition according to claim 1, the therapeutic particles further comprising a biodegradable glass. 4. The therapeutic composition according to claim 1, wherein the therapeutic particles have a mean particle size of 1 to 4 μm. 5. The therapeutic composition according to claim 1, wherein the carbohydrate is trehalose. 6. The therapeutic composition according to claim 1, wherein the protein is insulin. 7. The therapeutic composition according to claim 6, wherein the therapeutic particles have a mean particle size of 1 to 4 μm. 8. The therapeutic composition according to claim 1, wherein the protein is insulin and the carbohydrate is trehalose. 9. The therapeutic composition according to claim 8, wherein the therapeutic particles have a mean particle size of 1 to 4 μm. 10. The therapeutic composition according to claim 1, the therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction. 11. The therapeutic composition according to claim 1, wherein the bioactive material is stabilized for storage at elevated temperature for one month. 12. The therapeutic composition according to claim 1, wherein the therapeutic composition is suitable for delivering the bioactive material by transalveolar administration. 13. A therapeutic composition in solid dose form comprising a bioactive material and a carbohydrate, wherein a) the bioactive material is a protein, b) the therapeutic composition comprises therapeutic particles in a glassy state, c) the therapeutic composition is a powder having a particle size distribution suitable for pulmonary administration, d) the bioactive material and the carbohydrate are dispersed within the therapeutic particles of the powder, e) the therapeutic particles further comprise a glass modifier, wherein the glass modifier is not the bioactive material, f) the carbohydrate is selected from the group consisting of monosaccharides, disaccharides and sugar alcohols, g) the therapeutic particles remain in the glassy state when stored at elevated temperature, wherein the elevated temperature is 60° C., h) the protein is distributed homogeneously and in solid solution in the carbohydrate, and i) the particles have a mean particle size of 0.5 to 5 μm. 14. The therapeutic composition according to claim 13, wherein the glass modifier is a protein. 15. The therapeutic composition according to claim 13, said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction. 16. The therapeutic composition according to claim 13, said therapeutic particles further comprising a biodegradable glass. 17. The therapeutic composition according to claim 13, wherein the therapeutic particles have a mean particle size of 1 to 4 μm. 18. The therapeutic composition according to claim 13, wherein the carbohydrate is a sugar alcohol. 19. The therapeutic composition according to claim 13, wherein the carbohydrate is trehalose. 20. The therapeutic composition according to claim 13, wherein the protein is insulin. 21. The therapeutic composition according to claim 20, wherein the therapeutic particles have a mean particle size of 1 to 4 μm. 22. The therapeutic composition according to claim 13, wherein the protein is insulin and the carbohydrate is trehalose. 23. The therapeutic composition according to claim 22, wherein the therapeutic particles have a mean particle size of 1 to 4 μm. 24. The therapeutic composition according to claim 13, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction. 25. The therapeutic composition according to claim 13, wherein the bioactive material is stabilized for storage at elevated temperature for one month. 26. The therapeutic composition according to claim 13, wherein the therapeutic composition is suitable for delivering the bioactive material by transalveolar administration. 27. The therapeutic composition according to claim 1, wherein the protein is insulin and the carbohydrate is a sugar alcohol. 28. The therapeutic composition according to claim 1 or 27, wherein the therapeutic particles remain in a glassy state at 70° C. 29. The therapeutic composition according to claim 28, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material. 30. The therapeutic composition according to claim 28, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction. 31. The therapeutic composition according to claim 28, said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction. 32. The therapeutic composition according to claim 28, wherein the composition is suitable for transalveolar administration. 33. The therapeutic composition according to claim 1, wherein the therapeutic particles remain in the glassy state when stored at elevated temperature for one month. 34. The therapeutic composition according to claim 33, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material. 35. The therapeutic composition according to claim 33, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction. 36. The therapeutic composition according to claim 33, wherein the therapeutic particles remain in the glassy state at 70° C. 37. The therapeutic composition according to claim 36, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material. 38. The therapeutic composition according to claim 36, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction. 39. The therapeutic composition according to claim 1, wherein the carbohydrate is a disaccharide. 40. The therapeutic composition according to claim 1, wherein the carbohydrate is a sugar alcohol. 41. The therapeutic composition according to claim 39 or 40, said therapeutic particles further comprising a glass modifier, wherein the glass modifier is not the bioactive material. 42. The therapeutic composition according to claim 39 or 40, said therapeutic particles further comprising an amino acid that is capable of inhibiting the Maillard reaction. 43. The therapeutic composition according to claim 39 or 40, wherein the therapeutic particles remain in the glassy state at 70° C. 44. The therapeutic composition according to claim 39 or 40, wherein the therapeutic particles remain in the glassy state when stored at elevated temperature for one month. 45. The therapeutic composition according to claim 3, wherein the biodegradable glass is a water soluble glass. 46. The therapeutic composition according to claim 45, wherein the protein is insulin. 47. The therapeutic composition according to claim 45, wherein the carbohydrate is a sugar alcohol. 48. The therapeutic composition according to claim 45 or 46 or 47, wherein the composition is suitable for transalveolar administration. 49. The therapeutic composition according to claim 48, wherein the therapeutic particles remain in the glassy state when stored at 60° C. for one month. 50. The therapeutic composition according to claim 49, said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction. 51. The therapeutic composition according to claim 45 or 46 or 47, wherein the therapeutic particles remain in the glassy state when stored at 60° C. for one month. 52. The therapeutic composition according to claim 45 or 46 or 47, said therapeutic particles further comprising a physiologically acceptable inhibitor of the Maillard reaction.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (324)
Dunlap Richard P. (Penfield NY) Hlasta Dennis J. (Clifton Park NY) Desai Ranjit C. (Colonie NY) Latimer Lee H. (Brighton NY) Subramanyam Chakrapani (East Greenbush NY) Court John J. (Colonie NY) Bell, 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use.
Crystal Ronald G. ; Dalemans Wilfried,BEX ; Perricaudet Michel,FRX ; Stratford-Perricaudet Leslie,FRX ; Pavirani Andrea,FRX, Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Livesey Stephen A.,AUX ; del Campo Anthony A. ; Nag Abhijit ; Nichols Ken B. ; Piunno Carmen ; Ross David P., Apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Zale Stephen E. (Hopkington MA) Burke Paul A. (Medford MA) Bernstein Howard (Cambridge MA) Brickner Avram (Brookline MA), Composition for sustained release of non-aggregated erythropoietin.
Platz, Robert M.; Patton, John S.; Foster, Linda; Eljamal, Mohammed, Compositions and methods for the pulmonary delivery of aerosolized macromolecules.
Puglia Wayne J. (Bellerose Village NY) Patanasinth Kanit J. (Tarrytown NY) Lombardo Andrew T. (Bronx NY) Beam John E. (Norwalk CT) Mackay Donald A. M. (Pleasantville NY), Compressed chewable antacid tablet and method for forming same.
Puglia Wayne J. (Bellerose Village NY) Patanasinth Kanit J. (Tarrytown NY) Lombardo Andrew T. (Bronx NY) Vink Walter (Purdys Station NY), Compressed chewable antacid tablet and method for forming same.
Schrder Ulf (Fagottgrnden 11 B S-223 68 Lund SEX), Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use the.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Shishov Nikolai M. (Moscow SUX) Zelenetsky Vladimir E. (Moscow SUX) Demina Nadezhda A. (Moscow SUX) Bondarev Ivan M. (Moscow SUX) Cherny Alexandr N. (Moscow SUX) Moskvitin Valery A. (Belgorod-Dnestro, Device for administering powdered substances.
Platz, Robert M.; Patton, John S.; Foster, Linda; Eljamal, Mohammed, Devices compositions and methods for the pulmonary delivery of aerosolized medicaments.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Platz Robert M. ; Patton John S. ; Foster Linda C. ; Eljamal Mohammed,LBX, Dispersible antibody compositions and methods for their preparation and use.
Platz Robert M. ; Patton John S. ; Foster Linda C. ; Eljamal Mohammed,LBX, Dispersible antibody compositions and methods for their preparation and use.
Burr John D. ; Smith Adrian E. ; Hall Randy K. ; Snyder Herman ; Schuler Carlos ; Axford George S. ; Ray Charles, Dry powder dispersing apparatus and methods for their use.
Burr, John D.; Smith, Adrian E.; Hall, Randy K.; Snyder, Herman; Schuler, Carlos; Axford, George S.; Ray, Charles, Dry powder dispersing apparatus and methods for their use.
Newhouse Michael T. (436 Queen Street South Hamilton ; Ontario CAX L8N 4A6) Baines W. Douglas (1675 Wedmore Way Mississauga ; Ontario CAX), Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow.
Prestrelski Steven J. (1971 W. Middlefield Rd. ; Unit #5 Mountain View CA 94043) Zhang Mei Z. (444 Via Colinas Thousand Oaks CA 91362), Formulation of a reconstituted protein, and method and kit for the production thereof.
Byron Peter R. (Richmond VA) Dalby Richard N. (Richmond VA), Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Ducheyne Paul (Rosemont PA) Radin Shulamith (Voorhees NJ) Santos Erick M. (Philadelphia PA), Incorporation of biologically active molecules into bioactive glasses.
Chien Yie W. (North Brunswick NJ) Kong-Jiann Li John (Plainsboro NJ) Liu Jue-Chen (East Brunswick NJ) Shi Wei-Min (Piscataway NJ) Siddiqui Ovais (Piscataway NJ) Sun Ying (King of Prussia PA), Iontotherapeutic device and process and iontotherapeutic unit dose.
Doat Bernard J. M. (Angers FRX) Letavernier Jean-Francois J. (Angers FRX) Aubard Gilbert G. (Palaiseau FRX) Llull Jean B. (Morsang sur Orge FRX) Calvet Alain P. (Versailles FRX) Junien Jean-Louis (Pa, Laxative composition based on lactulose and its preparation process.
Riggs John H. (201-F Foliage Cir. Cary NC 27511) Mangum Barry O. (P.O. Box 20554 Raleigh NC 27619), Low flow rate nebulizer apparatus and method of nebulization.
McCabe John M. (Pittsford NY) Wilson John C. (Rochester NY), Low fusing temperature toner powder of cross-linked crystalline and amorphous polyester blends.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Jung Christophe (Strasbourg FRX) Jung Jean (Strasbourg FRX), Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Szwergold Benjamin S. (Philadelphia PA) Brown Truman R. (Bedminster NJ) Kappler Francis (Philadelphia PA) Peterson Aqqaluk (Copenhagen DKX), Method for assessing risk of diabetes-associated pathologic conditions and efficacy of therapies for such conditions.
Malfroy-Camine Bernard (Arlington MA), Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier perm.
Corsello Vincent (Cedar Knolls NJ) Glass Michael (Fair Lawn NJ) Ross Norton (Randolph NJ) Hohclick Joseph (Hopatcong NJ) Bilka Kenneth P. (Floral Park NY), Method for increasing salivation for xerostomia patients.
McGinity James W. (Austin TX) Chang Kuei-Tu (Mountain Lakes NJ), Method for preparing a solid sustained release form of a functionally active composition.
Colaco Camilo,GBX ; Roser Bruce J.,GBX ; Sen Shevanti,GBX, Method for stabilization of biological substances during drying and subsequent storage and compositions thereof.
Colaco Camilo,GBX ; Roser Bruce J.,GBX ; Sen Shevanti,GBX, Method for stabilization of biological substances during drying and subsequent storage and compositions thereof.
Bachmann Peter A. (Veterinar-Str. 13 8000 Munich 22 DEX) Mayr Anton (Veterinar-Str. 13 8000 Munich 22 DEX), Method of preparing an attenuated transmissible gastroenteritis (TGE) virus strain for use in live vaccines.
Roser Bruce J. (Balsham GB2) Colaco Camilo (Trumpington GB2), Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sug.
Platz Robert M. ; Kimura Shigenobu,JPX ; Satoh Yu-ichiro,JPX ; Foster Linda C., Methods and compositions for the dry powder formulation of interferons.
Platz Robert M. ; Kimura Shigenobu,JPX ; Satoh Yu-ichiro,JPX ; Foster Linda C., Methods and compositions for the dry powder formulation of interferons.
Carson Dennis A. (Del Mar CA) Raz Eyal (San Diego CA), Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleoti.
Alan G. Tunnacliffe GB; David T. Welsh GB; Bruce J. Roser GB; Kamaljit S. Dhaliwal GB; Camilo Colaco GB, Methods of preserving prokaryotic cells and compositions obtained thereby.
Bernstein Howard (Cambridge MA) Straub Julie A. (Winchester MA) Brush Henry T. (Somerville MA) Wing Richard E. (Cambridge MA), Microencapsulated fluorinated gases for use as imaging agents.
Bot, Adrian I.; Tarara, Thomas E.; Weers, Jeffry G.; Kabalnov, Alexev; Schutt, Ernest G.; Dellamary, Luis A., Particulate delivery systems and methods of use.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Riggs John H. (3720 Summer Pl. Raleigh NC 27604) Mangum Barry O. (1105 Shadywood La. Raleigh NC 27603), Powder nebulizer apparatus and method of nebulization.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Devos Francis (Morbecque-Merville FRX) Bussiere Guy (La Gorgue FRX) Huchette Michel (Merville FRX), Process for hard coating with sorbitol and products obtained thereby.
Cohan Allan N. (1143 Wright Dr. Huntingdon Valley PA 19006), Process for producing round spherical free flowing blown bead food products of controlled bulk density.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Processes for preparing compositions for inhalation.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Benson Bradley J. (170 Cresta Vista Dr. San Francisco CA 94127) Wright JoRae (170 Cresta Vista Dr. San Francisco CA 94127), Pulmonary administration of pharmaceutically active substances.
Sarin Virender K. (Libertyville IL) Fox Jack L. (Lake Bluff IL) Gupta Shanker L. (Vernon Hills IL) Absolom Darryl R. (Columbus OH), Pulmonary surfactant protein fragments.
Boothroyd John C. (7 Westgate Road Beckenham ; Kent GB2) Cross George A. M. (37a The Grove Biggin Hill ; Westerham ; Kent GB2) Highfield Michael D. (107 South Eden Park Road Beckenham ; Kent GB2) Win, Recombinant DNA expression vector encoding for foot and mouth disease virus proteins.
Bodner Mordechai (San Diego CA) De Polo Nicholas J. (Solana Beach CA) Chang Stephen (Poway CA) Hsu David Chi-Tang (San Diego CA) Respess James G. (San Diego CA), Retroviral delivery of full length factor VIII.
Hlasta Dennis J. (Lower Salford Township ; Montgomery County PA) Ackerman James H. (Albany NY) Mura Albert J. (Rochester NY) Desai Ranjit C. (Towamencin Township ; Montgomery County PA), Saccharin derivative proteolytic enzyme inhibitors.
Knight Jack V. (Houston TX) Gilbert Brian E. (Houston TX) Wilson Samuel Z. (Houston TX) Six Howard R. (East Stroudsborg PA) Wyde Philip R. (Houston TX), Small particle aerosol liposome and liposome-drug combinations for medical use.
La Rochelle Paul J. (427 Beech St. Holyoke MA 01040), Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only.
Roser, Bruce J.; Colaco, Camilo; Jerrow, Mohammed A. Z.; Blair, Julian; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair, Solid delivery systems for controlled release of molecules incorporated therein and methods of making same.
Sutton Andrew D.,GBX ; Johnson Richard A.,GBX ; Senior Peter J.,GBX ; Heath David,GBX, Spray-dried microparticles and their use as therapeutic vehicles.
Goldin Stanley M. (Lexington MA) Katragadda Subbarao (Belmont MA) Hu Lain-Yen (Bedford MA) Reddy N. Laxma (Malden MA) Fischer James B. (Cambridge MA) Knapp Andrew G. (Salem MA) Margolin Lee D. (Belmo, Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for ident.
Andersson Jan (Sodra Sandby SEX) Jagfeldt Hans (Lund SEX) Trofast Eva (Lund SEX) Wetterlin Kjell (Sodra Sandby SEX), System for dispensing pharmaceutically active compounds.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Haber Terry M. (Lake Forest CA) Smedley William H. (Lake Elsinore CA) Foster Clark B. (Laguna Niguel CA), Timing and velocity controlled powered pharmaceutical inhaler.
Berger Jacob (Los Altos Hills) Clark Robin D. (Palo Alto) Eglen Richard M. (Mountain View) Smith William L. (Sunnyvale) Weinhardt Klaus K. (San Francisco CA), Tricyclic 5-HT3receptor antagonists.
Sakon Kiyoyuki,JPX ; Sakagami Masahiro,JPX ; Makino Yuji,JPX ; Suzuki Yoshiki,JPX ; Kobayashi Hideki,JPX, Ultrafine particle power for inhalation and method for production thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.